Skip to content

Novartis targets Xolair successor in buyout of startup Excellergy

0.616
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Novartis will acquire Excellergy, a young allergy drugmaker, to gain access to an experimental therapy that could improve upon the widely used medication Xolair. The deal announced Friday could be worth as much as $2 billion overall when including the unspecified upfront payment as well as future payouts. It’s expected to close in the second half of the year, the companies said in a statement. At ...
The acquisition of Excellergy by Novartis is a strategic move aimed at improving upon the widely used medication Xolair with Exl-111, an experimental therapy targeting IgE. The deal reflects Novartis' strategy of investing in immune drug research and confronting patent expirations from key drugs like Entresto and Cosentyx through acquisitions. Patterns detected: ARC-0043 Motte-and-Bailey, ARC-0024 Ambiguity The deal is rooted in ...